VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Gemcitabine/Nab-Paclitaxel in Advanced Pancreatic Cancer

Panelists Francis P. Arena, MD, NYU Langone; Johanna Bendell, MD, Sarah Cannon;E. Gabriela Chiorean, MD, SCCA; Ramesh K. Ramanathan, MD, TGen
Published: Thursday, Feb 13, 2014
For High-Definition, Click
In September 2013, the combination of nab-paclitaxel and gemcitabine was approved as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas based on results from the phase III MPACT trial. This study showed that adding nab-paclitaxel to gemcitabine improved overall survival by nearly 2 months compared with gemcitabine alone (8.5 months versus 6.7 months), explains Ramesh K. Ramanathan, MD.

Due to differences in the clinical trial designs, it is difficult to compare the efficacy of the chemotherapy regimen FOLFIRINOX to the combination of nab-paclitaxel and gemcitabine, which makes selecting a first-line treatment difficult. Moreover, the panelists don’t believe a head-to-head trial comparing the two agents will ever happen.

At this point, E. Gabriela Chiorean, MD, notes that FOLFIRINOX appears to be more toxic. As a result, she prefers nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic pancreatic cancer.


Slider Left
Slider Right
For High-Definition, Click
In September 2013, the combination of nab-paclitaxel and gemcitabine was approved as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas based on results from the phase III MPACT trial. This study showed that adding nab-paclitaxel to gemcitabine improved overall survival by nearly 2 months compared with gemcitabine alone (8.5 months versus 6.7 months), explains Ramesh K. Ramanathan, MD.

Due to differences in the clinical trial designs, it is difficult to compare the efficacy of the chemotherapy regimen FOLFIRINOX to the combination of nab-paclitaxel and gemcitabine, which makes selecting a first-line treatment difficult. Moreover, the panelists don’t believe a head-to-head trial comparing the two agents will ever happen.

At this point, E. Gabriela Chiorean, MD, notes that FOLFIRINOX appears to be more toxic. As a result, she prefers nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic pancreatic cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x